Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Completed · Phase 2 · Has a placebo group

Conditions studied: Hypertension

In brief

The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial stiffness in elderly patients with an elevated systolic blood pressure (SBP) and widened pulse pressure (PP).

Key facts

Study ID
NCT01692301
Run by
Novartis Pharmaceuticals
People needed
454
Starts
2012-12-01
Expected to finish
2015-04-01
Last updated by the study team
2016-05-04

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.